Document is current

Article History

Received: 22 August 2024

Accepted: 30 September 2024

First Online: 25 October 2024

Declarations

:

: April W. Armstrong is a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, Leo, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Ahmed M. Soliman, Siran Fang, and Manish Patel are full-time employees of AbbVie and may hold AbbVie stock and/or stock options and patents. Paolo Gisondi has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo-pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi, UCB. Bruce Strober has served as a consultant (received honoraria) for AbbVie, Acelyrin, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Kangpu Pharmaceuticals, Bristol-Myers-Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Imagenebio, Janssen, Leo, Eli Lilly, Maruho, Okura, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, and Union Therapeutics. He owns stock options in Connect Biopharma and Mindera Health. He has served as a speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme and as a co-scientific director (consulting fee) and investigator for CorEvitas Psoriasis Registry. He also serves as editor-in-chief (honorarium) for<i> The Journal of Psoriasis and Psoriatic Arthritis</i>.

: This study, and each clinical trial included in the analysis, was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and was consistent with International Conference on Harmonization Good Clinical Practice, Good Epidemiology Practices, and applicable regulatory requirements [, , ]. This analysis utilized de-identified data from published clinical trial data; thus no ethics committee approval was required. However, each individual trial included in this analysis was approved by independent ethics committees or institutional review boards at each study site and all patients provided written informed consent before enrolling in each clinical trial [, , ].